A myeloid cell population induced by freund adjuvant suppresses T-cell-mediated antitumor immunity

Journal of Immunotherapy

Volumn 33, Issue 2, 2010, Pages 167-177

  Wang, Zibing ^a,b,c   Jiang, Jing ^a,b,c   Li, Zhiguang ^a,b,c   Zhang, Jinhua ^a,b   Wang, Hui ^d   Qin, Zhihai ^a,b  

^a National Laboratory of Biomacromolecules   (China)

^b China Japan Joint Laboratory of Structural Virology and Immunology   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Freund adjuvant; Myeloid cells; Nitric oxide; Tumor vaccine

Indexed keywords

CD11B ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TUMOR CELL VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER GRAFT; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; FEMALE; FIBROSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REJECTION;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD11B; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; FREUND'S ADJUVANT; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 77649172232     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181bed2ba     Document Type: Article

References (55)

1. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med. 1996; 2:1038-1041.
2. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
3. Finn OJ. Cancer immunology. N Engl J Med. 2008;358: 2704-2715.
4. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol. 2004;16:143-150.
5. Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol Ther. 2003;2:S161-168.
6. Mocellin S, Mandruzzato S, Bronte V, et al. Part I: vaccines for solid tumors. Lancet Oncol. 2004;5:681-689.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
8. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281-287.
9. Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat Immunol. 2000;1:363-366.
10. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol. 2001;1:209-219.
11. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227-238.
12. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27:687-690.
13. Gohara R, Imai N, Rikimaru T, et al. Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J Immunother. 2002;25:439-444.
14. Mine T, Sato Y, Noguchi M, et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res. 2004;10:929-937.
15. Schaed SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002;8:967-972.
16. Smith JW II, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 2003;21:1562-1573.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
18. Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol. 2006;177:6527-6539.
19. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
20. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 1985;45:1657-1662.
21. Oi VT, Morrison SL, Herzenberg LA, et al. Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci USA. 1983;80:825-829.
22. Zhao X, Mohaupt M, Jiang J, et al. Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res. 2007;67: 4443-4450.
23. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006;12:335-341.
24. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12:677-686.
25. Jordan MB, Mills DM, Kappler J, et al. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004;304:1808-1810.
26. Dighe AS, Richards E, Old LJ, et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447-456.
27. Ibe S, Qin Z, Schuler T, et al. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med. 2001;194:1549-1559.
28. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836-848.
29. Blankenstein T, Qin Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcino-genesis. Curr Opin Immunol. 2003;15:148-154.
30. Li Z, Pradera F, Kammertoens T, et al. Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection. J Immunol. 2007;179:1568-1576.
31. Qin Z, Schwartzkopff J, Pradera F, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003;63:4095-4100.
32. + T cells in patients with melanoma. J Immunol. 2005;175:6169-6176.
33. Ulaeto D, Lacy PE, Kipnis DM, et al. A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant. Proc Natl Acad Sci USA. 1992;89:3927-3931.
34. Qin HY, Sadelain MW, Hitchon C, et al. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol. 1993;150:2072-2080.
35. Kahn DA, Archer DC, Gold DP, et al. Adjuvant immunother-apy is dependent on inducible nitric oxide synthase. J Exp Med. 2001;193:1261-1268.
36. Pekarek LA, Starr BA, Toledano AY, et al. Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995;181:435-440.
37. Beck C, Schreiber K, Schreiber H, et al. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol. 2003;33:19-28.
38. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004; 4:941-952.
39. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155-1166.
40. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931-939.
41. + mye-loid cells. Cancer Res. 2006;66:6807-6815.
42. Angulo I, de las Heras FG, Garcia-Bustos JF, et al. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood. 2000;95: 212-220.
43. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235-2249.
44. +/ Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol. 2006;176:2085-2094.
45. +Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol. 2002;169:3180-3190.
46. Brys L, Beschin A, Raes G, et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol. 2005;174:6095-6104.
47. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284-290.
48. Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67:10019-10026.
49. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-depen-dent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007;204:1463-1474.
50. + T lymphocytes after immunization: induction of a sup-pressive population of Mac-1+/Gr-1+ cells. J Immunol. 1998; 161:5313-5320.
51. Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168:689-695.
52. Dupuis M, De Jesus Ibarra-Sanchez M, Tremblay ML, et al. Gr-1+ myeloid cells lacking T cell protein tyrosine phospha-tase inhibit lymphocyte proliferation by an IFN-gamma-and nitric oxide-dependent mechanism. J Immunol. 2003;171: 726-732.
53. Liu Y, Van Ginderachter JA, Brys L, et al. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol. 2003;170:5064-5074.
54. MacDonald KP, Rowe V, Clouston AD, et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol. 2005;174: 1841-1850.
55. Billiau AD, Fevery S, Rutgeerts O, et al. Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood. 2003;102:740-748.